A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
pMMR/MSS and 32 dMMR/MSI-H patientspatients were planned to be enrolled. Patients with
dMMR/MSI-H will be randomly assigned to the immunotherapy arm or short-course radiotherapy
sequential immunotherapy arm; pMMR/MSS patients will receive capecitabine-irinotecan based
concurrent radiotherapy before being randomly assigned to the XELIRI or FOLFRINOX arm.
The rate of complete response (sustained cCR for ≥ 1 year), long-term prognosis and adverse
effects will be analyzed.